References
- Chen F, Yan Q, Yu Y, Wu MX. (2017). BCG vaccine powder-laden and dissolvable microneedle arrays for lesion-free vaccination. J Control Release 255:36–44.
- Chen X, Kositratna G, Zhou C, et al. (2014). Micro-fractional epidermal powder delivery for improved skin vaccination. J Control Release 192:310–16.
- Donnelly RF, Singh TRR, Woolfson AD. (2010). Microneedle-based drug delivery systems: microfabrication, drug delivery, and safety. Drug Deliv 17:187–207.
- Flynn JL, Chan J, Triebold KJ, et al. (1993). An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 178:2249–54.
- Fraser J, Laurent T, Laurent U. (1997). Hyaluronan: its nature, distribution, functions and turnover. J Internal Med 242:27–33.
- Gill HS, Denson DD, Burris BA, Prausnitz MR. (2008). Effect of microneedle design on pain in human volunteers. Clin J Pain 24:585.
- Günther G. (2014). Multidrug-resistant and extensively drug-resistant tuberculosis: a review of current concepts and future challenges. Clin Med 14:279–85.
- Hiraishi Y, Nandakumar S, Choi SO, et al. (2011). Bacillus Calmette-Guérin vaccination using a microneedle patch. Vaccine 29:2626–36.
- Kim YC, Park JH, Prausnitz MR. (2012). Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev 64:1547–68.
- Kumar MNK, Zhou C, Wu MX. (2016). Laser-facilitated epicutaneous immunotherapy to IgE-mediated allergy. J Control Release 235:82–90.
- Kupper TS, Fuhlbrigge RC. (2004). Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol 4:211.
- Liu W, Wang H, Yu J, et al. (2016). Structure, chain conformation, and immunomodulatory activity of the polysaccharide purified from Bacillus Calmette Guerin formulation. Carbohydr Polym 150:149–58.
- Matteelli A, Roggi A, Carvalho AC. (2014). Extensively drug-resistant tuberculosis: epidemiology and management. Clin Epidemiol 6:111.
- Mitragotri S. (2005). Immunization without needles. Nat Rev Immunol 5:905.
- Munsiff SS, Nivin B, Sacajiu G, et al. (2003). Persistence of a highly resistant strain of tuberculosis in New York City during 1990–1999. J Infect Dis 188:356–63.
- Parida S, Axelsson, Robertson R, et al. (2015). Totally drug‐resistant tuberculosis and adjunct therapies. J Intern Med 277:388–405.
- Rodriguez L, Tirado Y, Reyes F, et al. (2011). Proteoliposomes from Mycobacterium smegmatis induce immune cross-reactivity against Mycobacterium tuberculosis antigens in mice. Vaccine 29:6236–41.
- Saunders B, Briscoe H, Britton W. (2004). T cell‐derived tumour necrosis factor is essential, but not sufficient, for protection against Mycobacterium tuberculosis infection. Clin Exp Immunol 137:279–87.
- Sullivan SP, Murthy N, Prausnitz MR. (2008). Minimally invasive protein delivery with rapidly dissolving polymer microneedles. Adv Mater 20:933–8.
- Sun J, Hou J, Li D, et al. (2013). Enhancement of HIV-1 DNA vaccine immunogenicity by BCG-PSN, a novel adjuvant. Vaccine 31:472–9.
- Tirado Y, Puig A, Alvarez N, et al. (2015). Protective capacity of proteoliposomes from Mycobacterium bovis BCG in a mouse model of tuberculosis. Human Vaccines Immunother 11:657–61.
- Wang LH, Ye Y, Zhang YQ, Xiao T. (2014). Curative effect of BCG-polysaccharide nuceic acid on atopic dermatitis in mice. Asian Pacific J Tropical Med 7:913–17.
- Wei D, Chen T, Yan M, et al. (2015). Synthesis, characterization, antioxidant activity and neuroprotective effects of selenium polysaccharide from Radix hedysari. Carbohydr Polym 125:161–8.
- World Health Organization (WHO). 2016. Global tuberculosis report 2016. Geneva: WHO.
- Xiong C, Li Q, Lin M, et al. (2009). The efficacy of topical intralesional BCG‐PSN injection in the treatment of erosive oral lichen planus: a randomized controlled trial. J Oral Pathol Med 38:551–8.
- Xu X, Gu Z, Liu S, et al. (2015). Purification and characterization of a glucan from Bacillus Calmette Guerin and the antitumor activity of its sulfated derivative. Carbohydr Polym 128:138–46.